Market Place
Sourcing Support
J&J Eyes Earlier Myeloma Treatment With Ph. 3 Tecvayli Combo Win
16 Oct 2025 //
FIERCE PHARMA
J&J Faces First UK Lawsuits Over Baby Powder Cancer Link
15 Oct 2025 //
REUTERS
Ona Pharma Appoints Dr. Antoine Yver To Drive ADC Programs
14 Oct 2025 //
PHARMIWEB
Johnson & Johnson Boosts 2025 Sales Forecast After Q3 Results
14 Oct 2025 //
BUSINESSWIRE
Johnson & Johnson Declares Q4 2025 Dividend
14 Oct 2025 //
BUSINESSWIRE
J&J Chief Duato `Optimistic` Amid MFN Discussions With Trump
14 Oct 2025 //
FIERCE PHARMA
J&J Reveals Plan To Spin Off Its $9B Orthopedics Business
14 Oct 2025 //
FIERCE BIOTECH
Genmab Reports Darzalex Net Sales in Q3 2025
14 Oct 2025 //
GLOBENEWSWIRE
J&J Eyes Takeover Of Immunology Partner Protagonist: WSJ
11 Oct 2025 //
FIERCE BIOTECH
FDA Adds Label Warning to J&J`s and Legend Bio`s Cancer Therapy
10 Oct 2025 //
REUTERS
J&J Recommend Shareholders Reject “mini-Tender” Offer by Tutanota
10 Oct 2025 //
BUSINESSWIRE
Johnson & Johnson Showcases Major Depressive Disorder Portfolio
10 Oct 2025 //
PR NEWSWIRE
Johnson & Johnson Joins UBS Global Healthcare Conference
09 Oct 2025 //
BUSINESSWIRE
J&J Will Appeal $966M Award By LA Jury In Talcum Powder Lawsuit
07 Oct 2025 //
FIERCE PHARMA
Johnson & Johnson Joins Guggenheim Securities Healthcare Conf
06 Oct 2025 //
BUSINESSWIRE
FDA Approves Tremfya For Pediatric Plaque Psoriasis & Psoriatic
30 Sep 2025 //
PR NEWSWIRE
Icotrokinra Outperforms Deucravacitinib In Head-To-Head Trials
29 Sep 2025 //
PHARMAWEB
Johnson & Johnson Recieves Warning Letter
24 Sep 2025 //
FDA
TREMFYA® Gets US Approval for Subcutaneous Induction in UC Adults
20 Sep 2025 //
PR NEWSWIRE
J&J Gets Positive CHMP Opinion for Nipocalimab in gMG Patients
19 Sep 2025 //
GLOBENEWSWIRE
TECVAYLI & DARZALEX FASPRO Show Promise in New Myeloma Patients
19 Sep 2025 //
PR NEWSWIRE
TREMFYA Gets Positive CHMP Opinion for Ulcerative Colitis Ph 2
19 Sep 2025 //
GLOBENEWSWIRE
J&J`s IL-23 Drug Defeats Sotyktu in Phase 3 Psoriasis Trial
17 Sep 2025 //
PR NEWSWIRE
J&J to Present Neuropsychiatry Innovation at 2025 Psych Congress
15 Sep 2025 //
PR NEWSWIRE
Novartis Falls in Another IRA Price Negotiation Loss for Pharma
12 Sep 2025 //
FIERCE PHARMA
J&J Pursues 1st EMA Approval for Icotrokinra in Plaque Psoriasis
11 Sep 2025 //
GLOBENEWSWIRE
Dr Reddy’s Expands CNS Portfolio With Acquisition of Stugeron
10 Sep 2025 //
PRESS RELEASE
Cullinan, Taiho`s NSCLC Shows `Strong Activity`, Paves Way to FDA
10 Sep 2025 //
BIOSPACE
Ronovo Raises $67M for Surgical Robots with J&J Support
09 Sep 2025 //
FIERCE BIOTECH
US FDA approves J&J`s Bladder Cancer Treatment
09 Sep 2025 //
PRESS RELEASE
Johnson & Johnson Appoints John Morikis to Board of Directors
08 Sep 2025 //
BUSINESSWIRE
Johnson & Johnson to Join Bernstein`s 2nd Annual Healthcare Forum
08 Sep 2025 //
BUSINESSWIRE
AstraZeneca Strengthens Tagrisso`s Position Against J&J Rivalry
08 Sep 2025 //
FIERCE PHARMA
RYBREVANT & LAZCLUZE May Improve Survival in Lung Cancer
07 Sep 2025 //
GLOBENEWSWIRE
Johnson & Johnson to Host Investor Call on Q3 Results
03 Sep 2025 //
BUSINESSWIRE
J&J`s Imaavy Comes up Short in Rheumatoid Arthritis Study
02 Sep 2025 //
FIERCE PHARMA
J&J Drops Development of Arthritis Drug After Trial Setback
29 Aug 2025 //
REUTERS
J&J Boosts US Manufacturing Commitment by $2B Amid Tariff Threats
23 Aug 2025 //
BIOSPACE
AZ, Genentech, Merck top oncology HCP promotions: report
14 Aug 2025 //
FIERCE PHARMA
Johnson & Johnson Joins Morgan Stanley`s 23rd Global Conference
30 Jul 2025 //
BUSINESSWIRE
J&J and Legend Launch First Carvykti TV Ad for Multiple Myeloma
30 Jul 2025 //
FIERCE PHARMA
Boston Jury Awards $42M In Johnson Baby Powder Asbestos Case
29 Jul 2025 //
BUSINESSWIRE
J&J files with U.S. FDA to include new evidence in TREMFYA
29 Jul 2025 //
PR NEWSWIRE
Johnson & Johnson to Participate in 2025 Wells Fargo Health Conf
24 Jul 2025 //
BUSINESSWIRE
EU Okays IMBRUVICA for Untreated Mantle Cell Lymphoma
23 Jul 2025 //
GLOBENEWSWIRE
EU Clears DARZALEX for High-Risk Multiple Myeloma Treatment
23 Jul 2025 //
GLOBENEWSWIRE
EU Approves DARZALEX Faspro® for Multiple Myeloma
23 Jul 2025 //
PR NEWSWIRE
Pacira Bio Expands Zilretta Promotion via Strategic Collaboration
22 Jul 2025 //
GLOBENEWSWIRE
J&J Pursues 1st FDA Approval for Icotrokinra in Plaque Psoriasis
21 Jul 2025 //
PR NEWSWIRE
J&J Gets FDA Priority Review For TAR-200 In High-Risk Cancer
18 Jul 2025 //
PR NEWSWIRE
Johnson & Johnson Raises 2025 Outlook After Q2 Results
16 Jul 2025 //
BUSINESSWIRE
Johnson & Johnson Declares Q3 2025 Quarterly Dividend
16 Jul 2025 //
BUSINESSWIRE
Real Chemistry Appoints Three to Catalyze Change
16 Jul 2025 //
FIERCE PHARMA
J&J Records High Innovative Drug Sales Amid Stelara`s Fall
16 Jul 2025 //
FIERCE PHARMA
J&J Raises Outlook Due to Increased Cardiac Device Sales
16 Jul 2025 //
FIERCE BIOTECH
Caplyta`s Fda Application Shows Schizophrenia Relapse Prevention
09 Jul 2025 //
PR NEWSWIRE
J&J Defeats Generic Drugmakers in Appeal Over Schizophrenia Drug
09 Jul 2025 //
REUTERS
J&J seeks EMA approval to expand Akeega
04 Jul 2025 //
GLOBENEWSWIRE
Janssen’s Biologics Stelara Receives Suppl Approval in US
27 Jun 2025 //
FDA
Nipocalimab better than FcRn blockers for gMG in 24-week study
25 Jun 2025 //
GLOBENEWSWIRE
